Sign in
Active, not recruitingNo phase

Retrospective Analysis of a Psoralea Corylifolia (Buguzhi)-Containing TCM Formula for Gastrointestinal Cancers

Key facts

Who runs it
Peking University Cancer Hospital & Institute
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
120 people, planned
Started
1 Jan 2026
Expected to end
31 Dec 2028
Type of study
Observational
Treatments tested
  • Psoralea corylifolia-Containing TCM Formula
Record updated
12 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (8)Hide the full registry criteria

Who can take part

  • Pathologically confirmed diagnosis of Gastrointestinal cancers, including esophageal squamous cell carcinoma, gastric cancer, hepatocellular carcinoma, or colorectal cancer
  • Received TCM formulas containing Psoralea corylifolia as part of routine clinical care
  • Available baseline and post-treatment imaging (CT or MRI) for RECIST 1.1 response assessment
  • Available KPS performance status records before and after treatment
  • Complete clinicopathologic and follow-up data

Who cannot take part

  • Concurrent other active malignancies
  • Incomplete medical records or missing imaging data
  • Less than 4 weeks of TCM formula treatment

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Psoralea corylifolia (Buguzhi) is a traditional Chinese medicine (TCM) herb with reported anti-tumor activity; its major bioactive compound, isobavachalcone (IBC), has been shown to inhibit ADORA3 and the downstream FAK/AKT/NF-κB signaling axis in gastrointestinal cancers. This is a retrospective, single-arm observational study reviewing medical records of approximately 120 patients with gastrointestinal cancers (esophageal squamous cell carcinoma, gastric cancer, hepatocellular carcinoma, and colorectal cancer; n=30 each) treated at Peking University Cancer Hospital who received TCM formulas containing Psoralea corylifolia as part of routine clinical care. The study evaluates changes in tumor response assessed by RECIST version 1.1 and in Karnofsky Performance Status (KPS) between baseline and 8-12 weeks after initiation of treatment.

The group in the trial

  • Psoralea corylifolia (Buguzhi)-Containing TCM Formula

    Patients with gastrointestinal cancers (esophageal squamous cell carcinoma (ESCC), gastric cancer (GC), hepatocellular carcinoma (HCC), and colorectal cancer (CRC)) who received TCM formulas containing Psoralea corylifolia (Buguzhi) as part of routine clinical care.

    Treatment: Psoralea corylifolia-Containing TCM Formula

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Retrospective Observational Study on the Clinical Efficacy of a Traditional Chinese Medicine Formula Containing Psoralea Corylifolia (Buguzhi) in Patients With Gastrointestinal Cancers
Record updated
12 November 2026